Global Bacteriophage Therapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Targeted Bacteria;

Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, and Others

By Route of Administration;

Oral, Topical, and Parenteral

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn134655018 Published Date: June, 2025 Updated Date: July, 2025

Bacteriophage Therapy Market Overview

Bacteriophage Therapy Market (USD Million)

Bacteriophage Therapy Market was valued at USD 1,353.04 million in the year 2024. The size of this market is expected to increase to USD 1,981.34 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.6%.


Global Bacteriophage Therapy Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 5.6 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.6 %
Market Size (2024)USD 1,353.04 Million
Market Size (2031)USD 1,981.34 Million
Market ConcentrationMedium
Report Pages339
1,353.04
2024
1,981.34
2031

Major Players

  • Microgen
  • Micreos
  • ATCC
  • Intralytix Inc
  • Adaptive Phage Therapeutics
  • Armata pharmaceuticals Inc
  • LOCUS BIOSCIENCES INC
  • Delmont Laboratories Inc
  • Nextbiotics
  • Pherecydes Pharma
  • iNtODEWORLD Inc
  • Enbiotix
  • Fixed-Phage Limited
  • Cytophage Technologies Inc
  • Eliava Bio Preparations LTD
  • Phagelux, Inc
  • InnoPhage Ltd
  • TechnoPhage
  • Eligo Bioscience SA
  • BiomX Ltd

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Bacteriophage Therapy Market

Fragmented - Highly competitive market without dominant players


The Bacteriophage Therapy Market is witnessing strong momentum due to the increasing resistance to traditional antibiotics. With antibiotic resistance projected to impact over 70% of bacterial infections, phage-based treatments are gaining substantial attention. The natural ability of bacteriophages to selectively target bacterial pathogens is driving their adoption as precision antimicrobials, especially in resistant infections.

Technological Advancements Boosting Efficacy
Advances in genetic engineering and synthetic biology have significantly enhanced the efficacy and customization of bacteriophage therapies. These innovations have led to the development of engineered phages that can target multi-drug-resistant bacteria with higher precision. Over 60% of recent R&D efforts are now directed towards optimizing phage-host interactions and therapeutic formulation.

Surging Clinical Trials and Regulatory Engagement
An increasing number of clinical trials, estimated at over 45% growth in recent years, is accelerating the commercialization of phage therapies. Regulatory bodies are also showing greater engagement, with new frameworks emerging to fast-track novel antimicrobial treatments. These supportive measures are reinforcing the credibility and market potential of phage-based solutions.

Expanding Application in Chronic and Acute Infections
Bacteriophage therapy is being increasingly explored for conditions such as chronic wound infections, cystic fibrosis-related lung infections, and gastrointestinal disorders. Around 55% of therapeutic research is now focused on chronic infection management, highlighting the versatility of phages beyond acute cases. This broadening scope is expanding the treatment horizon across healthcare settings.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Targeted Bacteria
    2. Market Snapshot, By Route of Administration
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Bacteriophage Therapy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising antibiotic resistance
        2. Growing awareness of antibiotic limitations
        3. Demand for alternative therapies
        4. Biotech and microbiology advancements
        5. Personalized medicine focus
      2. Restraints
        1. Limited evidence and approvals
        2. Production challenges
        3. Lack of awareness
        4. Regulatory variability
        5. Safety and efficacy concerns
      3. Opportunities
        1. Diverse applications
        2. Phage cocktails usage
        3. Expanded clinical trials
        4. Enhanced manufacturing
        5. Addressing medical gaps
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Bacteriophage Therapy Market, By Targeted Bacteria, 2021-2031 (USD Million)
      1. Escherichia coli
      2. Staphylococcus
      3. Streptococcus
      4. Pseudomonas
      5. Salmonella
      6. Others
    2. Bacteriophage Therapy Market, By Route of Administration, 2021-2031 (USD Million)
      1. Oral
      2. Topical
      3. Parenteral
    3. Bacteriophage Therapy Market, By Distribution Channel, 2021-2031 (USD Million)

      1. Hospital Pharmacies

      2. Retail Pharmacies

      3. Online Pharmacies

    4. Bacteriophage Therapy Market, By Geography, 2021-2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Microgen
      2. Micreos
      3. ATCC
      4. Intralytix Inc
      5. Adaptive Phage Therapeutics
      6. Armata pharmaceuticals Inc
      7. LOCUS BIOSCIENCES INC
      8. Delmont Laboratories Inc
      9. Nextbiotics
      10. Pherecydes Pharma
      11. iNtODEWORLD Inc
      12. Enbiotix
      13. Fixed-Phage Limited
      14. Cytophage Technologies Inc
      15. Eliava Bio Preparations LTD
      16. Phagelux Inc
      17. InnoPhage Ltd
      18. TechnoPhage
      19. Eligo Bioscience SA
      20. BiomX Ltd
  7. Analyst Views
  8. Future Outlook of the Market